New lifeline for patients with inoperable neuroendocrine cancers

A novel drug proven to reduce the risk of disease progression by 79% as well as three new European Centres of Excellence, offer new hope to patients with inoperable metastatic advanced midgut neuroendocrine cancer. —> Read More

facebooktwittergoogle_plusredditpinterestlinkedinmail